Skip to content

Categoryadhd

Neuroimaging shows interactions in attention-based brain networks weaker in children with ADHD.

Currently, more than 6 million children in the United States, or 11% of all children aged 4 to 17, have received attention-deficit hyperactivity disorder (ADHD) diagnoses. The disorder is characterized … Continue Reading Neuroimaging shows interactions in attention-based brain networks weaker in children with ADHD.

Gene variants implicated in ADHD identify attention and language deficits in the general population.

A new study from researchers at Cardiff University and the University of Bristol suggests that there is a spectrum of attention, hyperactivity/impulsiveness and language function in society, with varying degrees … Continue Reading Gene variants implicated in ADHD identify attention and language deficits in the general population.

Review of ADHD drug approvals highlights gaps between approval process, long-term safety assessment.

Review of ADHD drug approvals highlights gaps between approval process, long-term safety assessment. Over the last 60 years, the U.S. Food and Drug Administration (FDA) approved 20 medications for attention deficit/hyperactivity disorder (ADHD) based on clinical trials that were not designed to study their long-term efficacy and safety or to detect rare adverse events. The study highlights gaps in how the long-term safety of drugs intended for chronic use in children is assessed as part of the FDA approval process.

Thoughts health innovators?

Translate »